{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-097591","form_type":"8-K","ticker":"TCRT","cik":"0001107421","company_name":"Alaunos Therapeutics, Inc.","filed_at":"2025-07-22T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.355066+00:00","generated_at":"2026-05-18T04:06:50.823590+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"confidence":"high","headline":"Alaunos Therapeutics Corporate Secretary Melinda Lackey to depart August 15, 2025","bullets":["Melinda Lackey notified company on 7/16/2025 of termination of consulting agreement effective 8/15/2025.","She will resign as Legal and Administrative Officer and Corporate Secretary on the effective date.","Departure not due to any disagreement with the company on operations, policies, or procedures.","No additional severance beyond accrued but unpaid compensation through effective date."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-097591","json":"https://secwatch.observer/filing/0000950170-25-097591.json","markdown":"https://secwatch.observer/filing/0000950170-25-097591.md","text":"https://secwatch.observer/filing/0000950170-25-097591.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1107421/000095017025097591/0000950170-25-097591-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1107421/000095017025097591/tcrt-20250716.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T04:06:50.823590+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}